Lotus Reports February 2026 Revenue of NT$2,238 Million

Taipei, Taiwan, 10 March 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for February 2026 of NT$2,238 million, representing an increase of 132% YoY, mainly driven by the consolidation of Alvogen US. Lotus's year-to-date (YTD) February 2026 revenue reached NT$4,290 million, an increase of 37% compared to the same period last year.

Lotus’ Asia business grew 4% YoY in YTD February 2026, continuing to be supported by the SEA and Korea markets. The US business posted a 14% MoM increase, reflecting continued solid demand across its portfolio following the resumption of shipments after temporary weather-related disruptions in January.

The acquisition of Alvogen has strengthened Lotus’ revenue base and product pipeline, helping to mitigate the impact of price erosion in the US lenalidomide market following the expiration of prior settlement agreements in January 2026. While lenalidomide revenue is expected to decline year-over-year in 2026 as market pricing adjusts to the new competitive environment, the product is expected to remain a meaningful contributor to Lotus. At the same time, the integration of Alvogen significantly broadens Lotus’ revenue base and product pipeline, creating additional growth opportunities for Lotus in 2026 and beyond.

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness